

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

CHANGE OF NON-EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Board resolved on 15 May 2026 that due to change of work arrangement, Mr. LIU Haijian (“**Mr. LIU**”) ceased to serve as the non-executive Director with immediate effect. Upon resignation as non-executive Director, Mr. LIU has also ceased to serve as a member of the remuneration and evaluation committee of the Board (the “**Remuneration and Evaluation Committee**”).

Mr. LIU has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. LIU for his valuable contribution to the Group during his tenure of service.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. CHEN Kun (“**Mr. CHEN**”) has been appointed as a non-executive Director and a member of the Remuneration and Evaluation Committee, with effect from 15 May 2026.

The biographical details of Mr. CHEN are set out below:

Mr. CHEN Kun, aged 54, obtained bachelor of laws degree from Chinese people’s Liberation Army University of International Relations in July 1994, and held qualification of engineer.

Mr. CHEN has a diverse professional background, having served as deputy director of the First Analysis Division at the China Anti-Money Laundering Monitoring and Analysis Center of the People’s Bank of China, and as director (division head) of the Eighth Discipline Inspection and Supervision Office of the Discipline Inspection and Supervision Group of the Central Commission for Discipline Inspection and the National Commission of Supervision stationed at the State-owned Assets Supervision and Administration Commission of the State Council.

Mr. CHEN joined China National Pharmaceutical Group Co., Ltd. (“**CNPGC**”) in November 2019, where he served as deputy secretary of the Discipline Inspection Committee. From February 2021 to December 2025, he served as secretary of the Discipline Inspection Committee and a member of the Party Committee of China National Biotec Group Company Limited. Mr. CHEN has served as a full-time external director of CNPGC since December 2025.

Mr. CHEN will enter into an appointment letter with the Company in relation to his appointments as the non-executive Director for an initial term of three years. He shall hold office only until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election. Thereafter, he is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The Director’s fee of Mr. CHEN would be determined and paid by CNPGC with reference to his responsibilities scope, performance and prevailing market condition. It is expected that he will not receive any Director’s fee from the Company.

Save as disclosed above, Mr. CHEN (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointments and professional qualifications; and (iv) does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

As at the date of this announcement, Mr. CHEN does not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. CHEN that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to Mr. CHEN that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express welcome to Mr. CHEN for his appointment as the non-executive Director.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 15 May 2026

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui, Mr. CHEN Kun and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.